Ovarian cancer patients with BRCA1/2 mutations were inherently more sensitive to platinum-based chemotherapy than patients with wild-type ovarian cancer [25], and the benefits of using PARPi inhibitors versus platinum-based chemotherapy at the same relapse stage were still uncertain. The gene discussed is BRCA1; the disease is ovarian carcinoma.